Anti-Obesity Drugs

Global Market Trajectory & Analytics

MCP-1722

EXECUTIVE ENGAGEMENTS

POOL

2273
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

409
Interactions with Platform & by Email

PARTICIPANTS

68
Unique # Participated

VALIDATIONS

22
Responses Validated*

COMPANIES

23
Responses Validated*
* Login for a full stack data experience

DATE

JAN 2022

TABLES

202

PAGES

264

EDITION

18

PRICE

USD 5450

CODE

MCP-1722


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

S M N T

%

VALIDATED RESEARCH *

S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T
S M N T

* S = Strong; M = Moderate; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
  

HIGHLIGHTS & REPORT INDEX

Amid the COVID-19 crisis, the global market for Anti-Obesity Drugs estimated at US$1.5 Billion in the year 2020, is projected to reach a revised size of US$5.1 Billion by 2027, growing at a CAGR of 19.4% over the period 2020-2027.
The Anti-Obesity Drugs market in the U.S. is estimated at US$443.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$903.4 Million by the year 2027 trailing a CAGR of 19% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 17.2% and 16.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 13.5% CAGR.

SELECT PLAYERS

Eisai Co. Ltd. (Japan); F. Hoffmann-La Roche Ltd. (Switzerland); GlaxoSmithKline Plc; Novo Nordisk A/S (Denmark); Rhythm Pharmaceuticals (US); VIVUS Inc. (US)

SEGMENTS

» Segment (Anti-Obesity Drugs)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Obesity and Overweight Statistics
Recent Market Activity
Obesity - A Prelude
Anti-Obesity Drugs: A Market Characterized by High Unmet Needs
Currently Available Anti-Obesity Medications
Select Currently Available Short-term and Long-term Anti-Obesity Medication
Select Off-Label Drugs for Obesity
Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth
Semaglutide: Highest Potential in the AOM Pipeline
Setbacks of Past Drugs
Positive Road Ahead for Belviq
Relaunch of Xenical
Relaunch of Contrave®
Reluctance among Patients, Physicians, and Payers Hurts Market Prospects
New Drug Development - High on the Agenda, Despite the Market Restraints
Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018
Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018
Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018
Diabetes Drug Companies Attempt to Foray into the Anti-Obesity Drugs Space
Competitive Landscape
Novo Nordisk - The Leading Player in the Market
The United States - The Largest Obesity and Anti-Obesity Market
Europe - A Market with Vast Potential
Obesity Creeps Up in Developing Countries
2. FOCUS ON SELECT PLAYERS
F. Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline Plc. (UK)
Eisai Co., Ltd. (Japan)
Novo Nordisk A/S (Denmark)
Rhythm Pharmaceuticals (USA)
VIVUS, Inc. (USA)
3. MARKET TRENDS & DRIVERS
Alarming Rise in Global Obesity Levels - The Major Growth Factor
Classification of BMI
Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion
Growing Middle Class Population to Drive the Market Growth
Childhood Obesity - A Market with Unmet Needs
Commercial Weight-Loss Companies Foray into the Market
Online Drug Stores Boost Sales
Barriers to Development of Effective Drugs
Regulatory Additions - A Barrier to Entry?
High Drug Development Costs - A Major Setback
Weight Loss Alternatives - A Market Dampener
4. GLOBAL MARKET PERSPECTIVE
World Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
World 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
UNITED STATES
USA Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
CANADA
Canada Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
JAPAN
Japan Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
CHINA
China Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
EUROPE
Europe Current & Future Analysis for Anti-Obesity Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
Europe 7-Year Perspective for Anti-Obesity Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
FRANCE
France Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
GERMANY
Germany Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
ITALY
Italy Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
UNITED KINGDOM
UK Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
REST OF EUROPE
Rest of Europe Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
ASIA-PACIFIC
Asia-Pacific Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
REST OF WORLD
Rest of World Current & Future Analysis for Anti-Obesity Drugs by Segment - Anti-Obesity Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
Total Companies Profiled: 23

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com